Literature DB >> 12556005

Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device.

D Price1, M Thomas, G Mitchell, C Niziol, R Featherstone.   

Abstract

A relationship has been reported between sub-optimal inhaler technique and control of asthma symptoms. Randomised controlled trials and systematic reviews may fail to accurately represent this relationship, by excluding patients who are unable to correctly use the reviewed devices. Breath actuated inhalers (BAIs) are reported to be easier to use than metered dose inhalers (MDIs). This study uses a large primary care medical record database (DIN-LINK) to examine the 'real-life' clinical effectiveness of a BAI vs. traditional MDIs. A comparison is made between the quantity of asthma-related medication (beta2 agonist, oral steroids and antibiotics) and healthcare resource use required by children (0-12 years) and adults (13+ years) using either the BAI or an MDI over a 12-month period. Out of 5556 new asthma patients who met the inclusion criteria, 306 used a BAI and 5250 used a traditional MDI. Children and adults using the BAI received fewer prescriptions for all three medication types than those using a traditional MDI (children: beta2 agonists -18% P=0.036, oral steroids -88% P<0.05, antibiotics -68% P<0.05 and adults: beta2 agonists -10.9% P=0.179, oral steroids -51.2% P<0.05, antibiotics -19.5% P=0.276). All prescription results reached statistical significance, with the exception of beta2 agonist and antibiotic prescription numbers for adult patients. Children and adults using the BAI required less GP consultations for asthma (children -30.3%, P<0.05 and adults -22.9%, P<0.05) and less GP consultations for respiratory infections than those using a traditional MDI (children -35.2%, P=0.001 and adults -10.4%, P=0.236). Adults using the BAI required less outpatient appointments than adults using an MDI (-43.7%, P=0.166). All non-prescription resource results reached statistical significance with the exception of GP consultations for respiratory infections and outpatient visits in the adult group. In conclusion, children and adults using the BAI appear to have better asthma control than children and adults using an MDI as evidenced by fewer relief medication prescriptions and less healthcare resource use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556005     DOI: 10.1053/rmed.2002.1426

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  12 in total

Review 1.  The paradox of adult asthma control: "who's in control anyway?".

Authors:  Rick Hodder
Journal:  Can Respir J       Date:  2007 May-Jun       Impact factor: 2.409

Review 2.  Drug-targeting methodologies with applications: A review.

Authors:  Clement Kleinstreuer; Yu Feng; Emily Childress
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

3.  Comparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients.

Authors:  Thomas Voshaar; Monica Spinola; Patrick Linnane; Alice Campanini; Daniel Lock; Anthony Lafratta; Mario Scuri; Barbara Ronca; Andrea S Melani
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-12-03       Impact factor: 2.849

4.  Scientific respiratory symposium, paris june 2010.

Authors:  Gavin Dalglish; Graham Priestley
Journal:  J Asthma Allergy       Date:  2011-06-29

5.  Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study.

Authors:  Linda Kemp; John Haughney; Neil Barnes; Erika Sims; Julie von Ziegenweidt; Elizabeth V Hillyer; Amanda J Lee; Alison Chisholm; David Price
Journal:  Clinicoecon Outcomes Res       Date:  2010-07-01

6.  Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD.

Authors:  David Price; John Haughney; Erika Sims; Muzammil Ali; Julie von Ziegenweidt; Elizabeth V Hillyer; Amanda J Lee; Alison Chisholm; Neil Barnes
Journal:  J Asthma Allergy       Date:  2011-04-28

7.  Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.

Authors:  Rick Hodder; Pat Ray Reese; Terra Slaton
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-06-11

Review 8.  Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.

Authors:  Richard Hodder; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19

9.  The challenge of delivering therapeutic aerosols to asthma patients.

Authors:  Federico Lavorini
Journal:  ISRN Allergy       Date:  2013-08-05

10.  Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD.

Authors:  Gabriella Gálffy; Györgyi Mezei; Gyula Németh; Lilla Tamási; Veronika Müller; Olof Selroos; Marta Orosz
Journal:  Drugs R D       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.